FDA Grants Novel Triplet Breakthrough Designation in BRAF+ mCRC

August 7, 2018 – The FDA has granted a breakthrough therapy designation to the combination of the BRAF inhibitor encorafenib, the MEK inhibitor binimetinib, and the EGFR inhibitor cetuximab for the treatment of patients with BRAF V600E–mutant metastatic colorectal cancer (mCRC) following 1 or 2 prior lines of treatment in the metastatic setting. The designation, which will expedite the development and review of the novel triplet in this setting, is based on … (leggi tutto)